Pharsight Launches PK Accelerator

Pharsight Corporation (NASDAQ:PHST) , is launching PK Accelerator (PKA(TM)), a system of bundled software coupled with a rapid deployment service provided at a fixed price and fixed scope. Adopting PK Accelerator will allow small to mid-sized organizations to deploy Pharsight's "best practices" solution for end-to-end pharmacokinetic analysis and validatable CFR 21 part 11 reporting in as little as 90 days.

Small to mid-sized research oriented pharmaceutical and biotech companies deploying PK Accelerator will be able to take advantage of the operational efficiencies Pharsight's enterprise and desktop software packages were designed to deliver. The software components of the PKA bundle will consist of the Pharsight(R) Knowledgebase Server(TM) (PKS), WinNonlin(R) Autopilot(TM), PKS Reporter(TM), the PKS and WinNonlin Validation Suites(TM), upgrades to WinNonlin Enterprise, and a choice of two of the following database connectors: Watson(TM), Excel(TM), or CDISC. All of these components have been designed for seamless interoperability and will be implemented as a complete system with minimal configuration. PK Accelerator will bring state-of-the-art clinical pharmacology archiving, analysis, and reporting capabilities within reach of smaller firms by standardizing the system's training and deployment procedures and leveraging Pharsight's best practices recommendations for system configuration and implementation. Standardized connector settings and transformations, standardized validation scripts, standardized software settings, standardized analysis and reporting templates and standardized business rules will all work together to improve the ROI for Pharsight's PK accelerating technologies.

"PK Accelerator allows you to integrate data into standardized PK-ready analysis formats, perform the analysis, and generate final NCA reports in as little as a day," said Shawn O'Connor, president, chief executive officer and chairman of Pharsight. "Pharsight is leveraging its lessons learned on 22 previous PKS and numerous AutoPilot and Reporter deployments and streamlining the process in order to accommodate the needs of small to mid-sized pharma and biotech companies."